Focused Ultrasound (FUS) paired with systemically-injected microbubbles (μB) is capable of transiently opening the blood–brain barrier (BBBO) for noninvasive and targeted drug delivery to the brain. FUS-BBBO is also capable of modulating the neuroimmune system, further qualifying its therapeutic potential for neurodegenerative diseases like Alzheimer’s disease (AD). Natural aging and AD impose significant strain on the brain and particularly the BBB, modifying its structure and subsequently, its functionality. The emerging focus on treating neurodegenerative diseases with FUS-BBBO necessitates an investigation into the extent that age and AD affect the BBB’s response to FUS. FUS-BBBO was performed with a 1.5-MHz, geometrically focused transducer operated at 450 kPa and paired with a bolus microbubble injection of 8 × 108 μB/mL. Here we quantify the BBBO, BBB closing (BBBC) timeline, and BBB permeability (BBBP) following FUS-BBBO in male mice with and without AD pathology, aged 10 weeks, one year, or two years. The data presented herein indicates that natural aging and AD pathology may increase initial BBBO volume by up to 34.4% and 40.7% respectively, extend BBBC timeline by up to 1.3 and 1.5 days respectively, and increase BBBP as measured by average Ktrans values up to 80% and 86.1% respectively in male mice. This characterization of the BBB response to FUS-BBBO with age and AD further clarifies the nature and extent of the functional impact of these factors and may offer new considerations for planning FUS-BBBO interventions in aged and AD populations.
The amyloid-β (Aβ) hypothesis implicates Aβ protein accumulation in Alzheimer’s disease (AD) onset and progression. However, therapies targeting Aβ have proven insufficient in achieving disease reversal, prompting a shift to focus on early intervention and alternative therapeutic targets. Focused ultrasound (FUS) paired with systemically-introduced microbubbles (μB) is a non-invasive technique for targeted and transient blood–brain barrier opening (BBBO), which has demonstrated Aβ and tau reduction, as well as memory improvement in models of late-stage AD. However, similar to drug treatments for AD, this approach is not sufficient for complete reversal of advanced, symptomatic AD. Here we aim to determine whether early intervention with FUS-BBBO in asymptomatic AD could delay disease onset. Thus, the objective of this study is to measure the protective effects of FUS-BBBO on anxiety, memory and AD-associated protein levels in female and male triple transgenic (3xTg) AD mice treated at an early age and disease state. Here we show that early, repeated intervention with FUS-BBBO decreased anxiety-associated behaviors in the open field test by 463.02 and 37.42% in male and female cohorts, respectively. FUS-BBBO preserved female aptitude for learning in the active place avoidance paradigm, reducing the shock quadrant time by 30.03 and 31.01% in the final long-term and reversal learning trials, respectively. Finally, FUS-BBBO reduced hippocampal accumulation of Aβ40, Aβ42, and total tau in females by 12.54, 13.05, and 3.57%, respectively, and reduced total tau in males by 18.98%. This demonstration of both cognitive and pathological protection could offer a solution for carriers of AD-associated mutations as a safe, non-invasive technique to delay the onset of the cognitive and pathological effects of AD.
Gene therapy for neurodegenerative diseases faces significant challenges due to the blood-brain barrier (BBB), which limits drug delivery to the central nervous system (CNS). While clinical trials for Parkinson’s disease (PD) have progressed, administration of vectors expressing enzymatic or neurotrophic factor transgenes have required extensive optimization of the delivery method to achieve potentially therapeutic levels of transgene expression. Focused ultrasound (FUS) combined with microbubbles has emerged as a promising non-invasive strategy to transiently open the BBB for targeted gene delivery via viral nanocarriers including recombinant adeno-associated viruses (AAVs). However, key factors influencing FUS-mediated AAV delivery, including dose distribution and therapeutic efficacy, remain underexplored in non-human primates (NHPs). Here, we evaluated the feasibility of AAV9-CAG-GFP delivery using two portable therapeutic ultrasound modalities: ultrasound-guided, spherically-focused FUS (USgFUS) and a novel low-frequency linear array configuration for imaging and therapy called theranostic ultrasound (ThUS). In mice, FUS-sonicated regions exhibited a 25-fold increase in AAV9 biodistribution compared to systemic injection alone. Extending this approach to NHPs, we observed up to a 200-fold increase in AAV9 DNA in treated brain regions, including PD-relevant structures. In assessing the translational therapeutic potential of this technique, ThUS-mediated AAV9-hSyn-hNTRN (human neurturin) delivery in a toxin mouse model of PD facilitated the rescue of up to 80% and 75% of degenerated dopaminergic neurons in the substantia nigra and striatum, respectively. These findings demonstrate that portable ultrasound technologies can non-invasively enhance AAV9 delivery to targeted brain regions in both mice and NHPs relative to what can be achieved with intravenous (IV) delivery of the same capsid alone. With further development, these approaches may offer a clinically viable, non-invasive alternative for gene therapy in neurodegenerative diseases. One sentence summary: BBB opening with portable therapeutic ultrasound non-invasively increased viral gene delivery to the brain after systemic AAV vector administration in mice and rhesus macaques.
Focused Ultrasound (FUS) is capable of opening the Blood-Brain Barrier (BBBO) in a reversible and targeted manner for the purposes of drug delivery and neuroimmune modulation. FUS-BBBO has been used to reduce Alzheimer's Disease (AD)-associated pathologies in murine models of progressed AD, however new discoveries about the role of AD pathology in disease onset and progression motivates an investigation into factors upstream of pathology accumulation. Here we investigate the ability of monthly FUS-BBBO sessions for preventing the onset and progression of AD pathology in male and female 3xTg mice. Four monthly sessions of FUS-BBBO effectively prevent the accumulation of Amyloid- ${\beta}(\mathbf{A}{\beta})$ and tau pathologies compared to age-matched., untreated controls.
Background: Focused Ultrasound‐induced Blood‐Brain Barrier Opening (FUS‐BBBO) has demonstrated preventative and therapeutic efficacy for improving cognitive and pathological decline in Alzheimer’s Disease (AD). Previous work has demonstrated highly specific binding of a novel Re complex (Re‐1) complex to amyloid‐β (Aβ) in vitro, subsequently inhibiting fibril formation and reducing Aβ‐induced cytotoxicity in neuronal cell cultures. The aim of this preliminary study is to evaluate the efficacy of early intervention combining FUS‐BBBO and Re‐1 for anxiety amelioration and memory improvement in a triple transgenic (3xTg)‐AD mouse model.Method: Four‐month‐old, male, triple transgenic (3xTg)‐AD mice, were divided into four groups for the present study: FUS+Re‐1, FUS, Re‐1, and anesthesia sham. This study consists of ten, bi‐weekly treatments spanning five months. Following treatment, the animals underwent five days of behavioral testing for anxiety (Open Field Test, OFT), spatial memory (Active Place Avoidance, APA), and reversal learning (Active Place Avoidance Reversal) to evaluate the progression of their AD‐associated cognitive deficits.Result: Here we report that the combination of FUS‐BBBO and Re‐1 delivery improves anxiety, long‐term spatial memory, and short‐term reversal learning, compared to FUS or Re‐1 alone, and compared to the anesthesia sham group. The amount of time elapsed in the center of the brightly lit OFT arena is inversely related to each animal’s level of anxiety; thus, the FUS+Re‐1 cohort and the FUS cohorts exhibited the lowest levels of anxiety across the four groups (Figure 1A). Next, the number of shocks delivered to each animal over the course of an Active APA learning trial is inversely related to that animal’s spatial memory capacity. Comparison of animal performance in the final trial of the first day of training, with the first trial of the subsequent day demonstrates that the FUS+Re‐1cohort had the best long‐term memory of the four cohorts (Figure 1B). The FUS+Re‐1 group also demonstrated the most consistent reversal learning improvement when comparing the first and third (final) trial on each of the two APA reversal trial days (Figure 1C‐D).Conclusion: This promising preliminary study offers evidence in support of early intervention with amyloid‐targeting Re‐1 and FUS‐BBBO for cognitive improvement in AD.